Metastatic malignant melanoma

Svetomir Nenad Markovic, L. A. Erickson, Thomas J Flotte, L. A. Kottschade, Robert R Mc Williams, James W Jakub, D. R. Farley, N. V. Tran, S. E. Schild, K. R. Olivier, S. Vuk-Pavlovic, Aleksandar D Sekulic, R. H. Weenig, Jose S Pulido, J. F. Quevedo, Richard Geoffrey Vile, G. A. Wiseman, I. Stoian, M. R. Pittelkow

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Metastatic malignant melanoma is an incurable malignancy with extremely poor prognosis. Patients bearing this diagnosis face a median survival time of approximately 9 months with a probability of surviving 5 years after initial presentation at less than 5%. This is contrasted by the curative nature of surgical resection of early melanoma detected in the skin. To date, no systemic therapy has consistently and predictably impacted the overall survival of patients with metastatic melanoma. However, in recent years, a resurgence of innovative diagnostic and therapeutic developments have broadened our understanding of the natural history of melanoma and identified rational therapeutic targets/strategies that seem poised to significantly change the clinical outcomes in these patients. Herein we review the state-of-the-art in metastatic melanoma diagnostics and therapeutics with particular emphasis on multidisciplinary clinical management.

Original languageEnglish (US)
Pages (from-to)1-26
Number of pages26
JournalGiornale Italiano di Dermatologia e Venereologia
Volume144
Issue number1
StatePublished - 2009

Fingerprint

Melanoma
Survival
Therapeutics
Skin
Neoplasms

Keywords

  • Melanoma, diagnosis
  • Metastases
  • Skin neoplasms

ASJC Scopus subject areas

  • Dermatology

Cite this

Metastatic malignant melanoma. / Markovic, Svetomir Nenad; Erickson, L. A.; Flotte, Thomas J; Kottschade, L. A.; Mc Williams, Robert R; Jakub, James W; Farley, D. R.; Tran, N. V.; Schild, S. E.; Olivier, K. R.; Vuk-Pavlovic, S.; Sekulic, Aleksandar D; Weenig, R. H.; Pulido, Jose S; Quevedo, J. F.; Vile, Richard Geoffrey; Wiseman, G. A.; Stoian, I.; Pittelkow, M. R.

In: Giornale Italiano di Dermatologia e Venereologia, Vol. 144, No. 1, 2009, p. 1-26.

Research output: Contribution to journalArticle

Markovic, SN, Erickson, LA, Flotte, TJ, Kottschade, LA, Mc Williams, RR, Jakub, JW, Farley, DR, Tran, NV, Schild, SE, Olivier, KR, Vuk-Pavlovic, S, Sekulic, AD, Weenig, RH, Pulido, JS, Quevedo, JF, Vile, RG, Wiseman, GA, Stoian, I & Pittelkow, MR 2009, 'Metastatic malignant melanoma', Giornale Italiano di Dermatologia e Venereologia, vol. 144, no. 1, pp. 1-26.
Markovic, Svetomir Nenad ; Erickson, L. A. ; Flotte, Thomas J ; Kottschade, L. A. ; Mc Williams, Robert R ; Jakub, James W ; Farley, D. R. ; Tran, N. V. ; Schild, S. E. ; Olivier, K. R. ; Vuk-Pavlovic, S. ; Sekulic, Aleksandar D ; Weenig, R. H. ; Pulido, Jose S ; Quevedo, J. F. ; Vile, Richard Geoffrey ; Wiseman, G. A. ; Stoian, I. ; Pittelkow, M. R. / Metastatic malignant melanoma. In: Giornale Italiano di Dermatologia e Venereologia. 2009 ; Vol. 144, No. 1. pp. 1-26.
@article{2af58032ddcf4c649d74d0e753cd8b65,
title = "Metastatic malignant melanoma",
abstract = "Metastatic malignant melanoma is an incurable malignancy with extremely poor prognosis. Patients bearing this diagnosis face a median survival time of approximately 9 months with a probability of surviving 5 years after initial presentation at less than 5{\%}. This is contrasted by the curative nature of surgical resection of early melanoma detected in the skin. To date, no systemic therapy has consistently and predictably impacted the overall survival of patients with metastatic melanoma. However, in recent years, a resurgence of innovative diagnostic and therapeutic developments have broadened our understanding of the natural history of melanoma and identified rational therapeutic targets/strategies that seem poised to significantly change the clinical outcomes in these patients. Herein we review the state-of-the-art in metastatic melanoma diagnostics and therapeutics with particular emphasis on multidisciplinary clinical management.",
keywords = "Melanoma, diagnosis, Metastases, Skin neoplasms",
author = "Markovic, {Svetomir Nenad} and Erickson, {L. A.} and Flotte, {Thomas J} and Kottschade, {L. A.} and {Mc Williams}, {Robert R} and Jakub, {James W} and Farley, {D. R.} and Tran, {N. V.} and Schild, {S. E.} and Olivier, {K. R.} and S. Vuk-Pavlovic and Sekulic, {Aleksandar D} and Weenig, {R. H.} and Pulido, {Jose S} and Quevedo, {J. F.} and Vile, {Richard Geoffrey} and Wiseman, {G. A.} and I. Stoian and Pittelkow, {M. R.}",
year = "2009",
language = "English (US)",
volume = "144",
pages = "1--26",
journal = "Giornale Italiano di Dermatologia e Venereologia",
issn = "0392-0488",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - Metastatic malignant melanoma

AU - Markovic, Svetomir Nenad

AU - Erickson, L. A.

AU - Flotte, Thomas J

AU - Kottschade, L. A.

AU - Mc Williams, Robert R

AU - Jakub, James W

AU - Farley, D. R.

AU - Tran, N. V.

AU - Schild, S. E.

AU - Olivier, K. R.

AU - Vuk-Pavlovic, S.

AU - Sekulic, Aleksandar D

AU - Weenig, R. H.

AU - Pulido, Jose S

AU - Quevedo, J. F.

AU - Vile, Richard Geoffrey

AU - Wiseman, G. A.

AU - Stoian, I.

AU - Pittelkow, M. R.

PY - 2009

Y1 - 2009

N2 - Metastatic malignant melanoma is an incurable malignancy with extremely poor prognosis. Patients bearing this diagnosis face a median survival time of approximately 9 months with a probability of surviving 5 years after initial presentation at less than 5%. This is contrasted by the curative nature of surgical resection of early melanoma detected in the skin. To date, no systemic therapy has consistently and predictably impacted the overall survival of patients with metastatic melanoma. However, in recent years, a resurgence of innovative diagnostic and therapeutic developments have broadened our understanding of the natural history of melanoma and identified rational therapeutic targets/strategies that seem poised to significantly change the clinical outcomes in these patients. Herein we review the state-of-the-art in metastatic melanoma diagnostics and therapeutics with particular emphasis on multidisciplinary clinical management.

AB - Metastatic malignant melanoma is an incurable malignancy with extremely poor prognosis. Patients bearing this diagnosis face a median survival time of approximately 9 months with a probability of surviving 5 years after initial presentation at less than 5%. This is contrasted by the curative nature of surgical resection of early melanoma detected in the skin. To date, no systemic therapy has consistently and predictably impacted the overall survival of patients with metastatic melanoma. However, in recent years, a resurgence of innovative diagnostic and therapeutic developments have broadened our understanding of the natural history of melanoma and identified rational therapeutic targets/strategies that seem poised to significantly change the clinical outcomes in these patients. Herein we review the state-of-the-art in metastatic melanoma diagnostics and therapeutics with particular emphasis on multidisciplinary clinical management.

KW - Melanoma, diagnosis

KW - Metastases

KW - Skin neoplasms

UR - http://www.scopus.com/inward/record.url?scp=66649136768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66649136768&partnerID=8YFLogxK

M3 - Article

C2 - 19218908

AN - SCOPUS:66649136768

VL - 144

SP - 1

EP - 26

JO - Giornale Italiano di Dermatologia e Venereologia

JF - Giornale Italiano di Dermatologia e Venereologia

SN - 0392-0488

IS - 1

ER -